gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Cysteinyl leukotriene receptor 1

cysteinyl leukotriene receptor, CysLT1, LTD4 receptor, CYSLTR1, cysteinyl leukotriene receptor 1
The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Pharmacologic studies have determined that cysteinyl leukotrienes activate at least 2 receptors, the protein encoded by this gene and CYSLTR2. This encoded receptor is a member of the superfamily of G protein-coupled receptors. Activation of this receptor by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: ACID, 5-lipoxygenase, HAD, CAN, V1a
Papers on cysteinyl leukotriene receptor
[Clinical significance of cysteinyl leukotriene receptor expression in primary hepatocellular carcinoma].
Ji et al., Jinan, China. In Zhonghua Gan Zang Bing Za Zhi, Jan 2016
OBJECTIVE: To investigate expression of the cysteinyl leukotriene receptor (CysLT1R) in hepatocellular carcinoma (HCC) tissues and determine its clinical significance.
Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors.
Sharma et al., India. In Curr Neurovasc Res, Dec 2015
The purpose of this study is to examine the role of ruthenium red; a selective RyR blocker as well as montelukast; a specific CysLT1 antagonist in CCH induced VaD in mice.
Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice.
Hong et al., Nanjing, China. In Psychopharmacology (berl), Dec 2015
RATIONALE: Numerous studies have demonstrated that neuroinflammation is associated with depression-like symptoms and neuropsychological disturbances, and cysteinyl leukotriene receptor 1 (CysLT1R) was reported to be involved in neuroinflammation.
Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: Does montelukast modulate antitumor and immunosuppressant effects of doxorubicin?
Abu Risha et al., Ţanţā, Egypt. In Toxicol Ind Health, Nov 2015
cysteinyl LT1 receptor; CysLT1R) has an important role in carcinogenesis.
Antileukotrienes in upper airway inflammatory diseases.
Şahin et al., Eskişehir, Turkey. In Curr Allergy Asthma Rep, Nov 2015
By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis.
Factors driving the aspirin exacerbated respiratory disease phenotype.
Borish et al., Charlottesville, United States. In Am J Rhinol Allergy, 2015
Finally, induction of LTC4S and CysLT1 receptors by IL-4 reflects in part the IL-4-mediated activation of signal transducer and activator of transcription 6 (STAT6).
The protective role of montelukast against intestinal ischemia-reperfusion injury in rats.
Shen et al., Yiwu, China. In Sci Rep, 2014
Intestinal IRI induced a marked increase in CysLTR1, Caspase-8 and -9 expression in intestine, liver and kidney, which were markedly reduced by preconditioning with 2 mg/kg montelukast.
Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion.
Neves et al., Rio de Janeiro, Brazil. In Biomed Res Int, 2014
Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R).
Molecular targets on mast cells and basophils for novel therapies.
Maurer et al., Kuopio, Finland. In J Allergy Clin Immunol, 2014
These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.
Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.
Feldman et al., Pretoria, South Africa. In J Immunol Res, 2013
Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast.
Increased cysteinyl leukotriene concentration and receptor expression in tonsillar tissues of Chinese children with sleep-disordered breathing.
Shen et al., Beijing, China. In Int Immunopharmacol, 2012
increased expression in tonsillar tissues of Chinese children with sleep-disordered breathing
The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia.
Möhle et al., Tübingen, Germany. In Leuk Lymphoma, 2012
Data suggest that CysLT1 induces chemokine-like effects, supports accumulation and survival of chronic lymphocytic leukemia (CLL) cells in the bone marrow and thus represents a potential treatment target.
Cysteinyl leukotriene type I receptor desensitization sustains Ca2+-dependent gene expression.
Parekh et al., Oxford, United Kingdom. In Nature, 2012
G-protein-coupled cysteinyl leukotriene type I (CysLT1) receptors regulate immune-cell function and CysLT1 receptors are an established therapeutic target for allergies, including asthma.
Leukotriene receptors are differently expressed in fibroblast from peripheral versus central airways in asthmatics and healthy controls.
Bjermer et al., Lund, Sweden. In Prostaglandins Leukot Essent Fatty Acids, 2011
cysteinyl-leukotriene receptors are differently expressed in fibroblast from peripheral versus central airways in asthmatics and healthy controls.
CysLT1-R expression following allergen provocation in asthma and allergic rhinitis.
Boulet et al., Québec, Canada. In Prostaglandins Leukot Essent Fatty Acids, 2010
CysLT1-R expression following allergen provocation in asthma and allergic rhinitis.
Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells.
Sjölander et al., Malmö, Sweden. In Plos One, 2009
upon ligand activation, CysLT(1)R is tyrosine-phosphorylated and released from heterodimers with CysLT(2)R and, subsequently, internalizes from the plasma membrane to the nuclear membrane in a clathrin-, arrestin-3-, and Rab-5-dependent manner
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.
Lee et al., London, United Kingdom. In N Engl J Med, 2002
We hypothesized that the latter effect reflects elevated expression of the cysteinyl leukotriene receptor CysLT1 on inflammatory cells in the target organ and that its expression is down-regulated by aspirin desensitization.
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
Evans et al., Charlottesville, United States. In Nature, 1999
Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT1 and CysLT2.
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.
Barnes et al., London, United Kingdom. In Lancet, 1991
In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart.
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects.
Dollery et al., London, United Kingdom. In Lancet, 1991
The effects of a highly selective leukotriene D4 receptor antagonist, ICI 204.219, on allergen-induced bronchoconstriction and changes in airway reactivity were evaluated in a double-blind, placebo-controlled, crossover trial.
share on facebooktweetadd +1mail to friends